Why CPH investors should care about The HighBrid Lab
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Last week, Creso Pharma Limited (ASX:CPH, FRA:1X8, OTC:COPHF) announced that it plans to merge its business with Red Light Holland Corp (CSE:TRIP, FRA:4Yx, OTC Pink:TRUFF) to become The HighBrid Lab.
Following much shareholder speculation, Bruce Linton, strategic advisor for Creso Pharma, spoke to The Dales Report to explain the reasoning behind the decision and multitude of opportunities the merger will uncover.
Watch the video below:
A Quick Recap
Red Light Holland is an Ontario-based corporation engaged in the production, growth and sale of magic truffles to the legal recreational market within the Netherlands.
Creso Pharma develops cannabis, hemp-derived therapeutic, nutraceuticals and lifestyle products. Creso has also targeted acquisition Halucenex Life Sciences, an established psychedelics group, for acquisition.
The merger entity of CPH and Red Light Holland to be known as The HighBrid Lab, will create a leading global psychedelics and cannabinoid company, specialising in recreational products, applied science, technology and innovation.
The HighBrid Lab will be able to immediately commence selling in the US.
What Does The Partnership Mean?
In the interview, Linton explained the key reasoning behind the merger, namely the difficulty of being in this particular industry as an ASX listed entity.
ASX regulations have prevented CPH from entering the US THC market and exploiting opportunities in that market - the largest cannabis market expected to reach $53 billion by 2025.
The merger will solve that problem by providing CPH with a Canadian Stock Exchange (CSE) listing, allowing for exposure to US THC assets, global opportunities relating to magic truffles, as well as strong science coming out of Switzerland – in Linton’s words, “a playing field where the science tells us how to make better care for animals and for humans”.
It also combines the strong brand image of Red Light Holland and a nod to the science of Creso Pharma.
Whilst ASX shareholders were surprised by the merger announcement, (it caused a 17% drop in share price on the day of announcement (17/6/21) Linton assured shareholders that the merger should give CPH shareholders access to a more aggressive market opportunity.
As a major shareholder himself, Linton highlighted the main driver for investors - action in growing markets including more deals and greater revenues.
The name of the new endeavour, The HighBrid Lab, was created to embody the “space where science, fun, and the grey zone of business all come together”.
A merged entity will allow for decreased double up of costs, and a much sharper focus on revenue generation than either company could ever do on its own.
Both entities present near term revenue generations, providing investors with even more regular global news flow despite the lengthy time frame of clinical trials.
The HighBrid Lab post COVID-19
Biotech innovation in the mental health space will see large strides taken in the post COVID world: Mental Illness will cost the world $16 USD Trillion by 2030.
As such, Bruce Linton discussed the prospect for policy makers worldwide to become much more receptive to a new class of mental health treatments - psychedelics.
With a strong cash balance and the creation of a skilled and passionate full time team, The HighBrid Lab is equipped with all the needed tools to be a strong mover in this space.
The Main Takeaway: Investors, just sit tight...
In closing, Linton left listeners with several key takeaways in why the HighBrid Lab merger makes sense and where shareholder value will be created:
- Lands in the right exchange (CSE) to move against any option
- Combined expertise opens access to more opportunities
- Access to the US THC market
- Consolidates cost base of being a listed entity to bring a stronger team into play
- Strong cash position
All these factors allow The HighBrid Lab to move with more speed than Creso Pharma and Red Light Holland could have ever done individually, with a bigger and improved breadth of opportunity.
Indeed, once the transaction is completed the HighBrid Lab will be the first fully complementary cannabis psychedelic company in the world.
For more details about the proposed merger read: What We DO and DON’T like about the proposed CPH Merger
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.